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Abstract: 
Infusion of carnitine has been observed to increase non-oxidative glucose disposal in several 
studies but the effect of oral carnitine on glucose disposal in non-diabetic lean vs. 
overweight/obese humans has not been examined. This study examined the effects of 14 days 
L-Carnitine L-Tartrate oral supplementation (LC) on blood glucose, insulin, NEFA and GLP-1 
responses to an oral glucose tolerance test (OGTT). Sixteen male participants were recruited 
(lean (n=8) and overweight/obese (n=8)). After completing a submaximal predictive exercise 
test, participants were asked to attend three experimental sessions. These three visits were 
conducted, in the morning to obtain fasting blood samples and to conduct 2hr OGTT’s. The first 
visit was a familiarisation trial and the final two visits were conducted two weeks apart following 
14 days of ingestion of placebo (PL, 3g glucose/day) then LC (3g LC/day) ingested as 2 
capsules 3x/day with meals. On each visit blood was drawn at rest, at intervals during the OGTT 
for analysis of glucose, insulin, non-esterified fatty acids (NEFA) and total glucagon-like peptide-
1 (GLP-1). Data obtained were used for determination of usual insulin sensitivity indices 
(HOMA-IR, AUC glucose, AUC insulin, 1st phase and 2nd phase β-cell function, estimated insulin 
sensitivity index, and estimated metabolic clearance rate). Data were analysed using 
RMANOVA and post-hoc comparisons where appropriate. There was a significant difference 
between groups for body mass, % fat and BMI with no significant difference in age and height. 
Mean (SEM) plasma glucose concentration at 30 minutes was significantly lower (p<0.05) in the 
lean group on the LC trial compared with PL (8.71(0.70) PL; 7.32(0.36) LC; mmol/L). 
Conversely, plasma glucose concentration was not different at 30 minutes but was significantly 
higher at 90 minutes (p<0.05) in the overweight/obese group on the LC trial (5.09(0.41) PL; 
7.11(0.59) LC; mmol/L). Estimated 1st phase and 2nd phase β-cell function both tended to be 
greater following LC in the lean group only. No effects of LC were observed on NEFA or total 
GLP-1 response to OGTT. It is concluded that LC supplementation induces changes in blood 
glucose handling/disposal during an OGTT which is not influenced by GLP-1. The glucose 
handling/disposal response to oral LC is different between lean and overweight/obese 
suggesting further investigation is required. LC effects on gastric emptying and/or direct ‘insulin-
like’ actions on tissues should be examined in larger samples of overweight/obese and lean 
participants, respectively. 
Introduction: 
L-Carnitine is a widely used conditionally essential nutrient added to a range of functional food 
products including weight loss formulations, infant formula milk, and sports bars and drinks. 
Carnitine is widely recognised as a key factor involved in the regulation and transport of 
activated fatty acids into mitochondria for oxidation (Brass and Hiatt, 1998) and thus many 
human studies have attempted to enhance skeletal muscle fatty acid oxidation by 
supplementing with carnitine (Abramowicz and Galloway, 2005; Broad et al 2005; Decombaz et 
al 1993; Hawley et al 1998a; Hawley et al 1998b; Vukovich et al 1994). The large majority of 
these studies have observed no effect of supplemental carnitine on whole body fat utilization of 
healthy active adults during moderate intensity exercise (for review see Galloway and Broad, 
2005), but there are observations of enhanced carbohydrate oxidation during exercise following 
oral supplementation in endurance trained male athletes (Abramowicz and Galloway, 2005). 
 
It is known that increasing the total carnitine content of skeletal muscle is difficult in the short 
term, but is attainable using hyperinsulinaemic euglycaemic clamp methodology to stimulate the 
sodium dependent transport of carnitine into skeletal muscle (Stephens et al 2006b) and 
through prolonged oral carnitine supplementation combined with carbohydrate (Wall et al 2010). 
Infusion of carnitine is associated with an increase in muscle glycogen content (Stephens et al 
2006a) and an elevated plasma carnitine concentration through infusion has been observed to 
increase non-oxidative glucose disposal during hyperinsulinaemic euglycaemic clamps in 
controls and type 2 diabetics (Giancaterini et al 2000; Mingrone et al 1999). It is interesting to 
note that Stephens et al (2007b) reported an increase in retention of oral carnitine when 
ingested with carbohydrate and attributed this to an increased muscle carnitine uptake, but 
these authors do not report muscle carnitine content, muscle glycogen data, or data on glucose 
disposal in response to oral carnitine ingestion. In their review (Stephens et al 2007a) it is 
reported that elevation in plasma carnitine likely increases glycogen storage through non-
oxidative glucose disposal which is consistent with the increased glucose disposal effect of 
elevating plasma carnitine via infusion observed in previous studies. The mechanism for this 
enhanced glucose disposal effect of carnitine has not been fully investigated, and glucose 
disposal responses to oral carnitine ingestion and glucose feeding have not been evaluated. 
Furthermore, investigation of oral carnitine ingestion on glucose disposal could potentially be 
influenced by differences in the incretin hormone response (components of the entero-insular 
axis that enhance the insulin response to a meal) and therefore incretin response should be 
monitored in any oral carnitine supplementation study. To date no-one has investigated the 
potential role of oral carnitine ingestion on glucose disposal. 
 
Since it is widely recognised that obesity is linked to impaired insulin sensitivity (Kahn et al 
2006), it is important to assess the potential effects of carnitine on insulin sensitivity indices and 
glucose disposal in lean to overweight/obese adults as they may respond differently to oral 
carnitine supplementation. Indeed, there is one report of enhanced whole body fat oxidation at 
rest in overweight participants following carnitine ingestion (Wutzke and Lorenz, 2004) which 
has not been observed in lean participants. Therefore, the primary aim of the present study was 
to evaluate whether oral supplementation with carnitine could impact upon insulin sensitivity 
indices and glucose disposal during an oral glucose tolerance test after an overnight fast in 
healthy lean and overweight/obese males. The secondary aim was to investigate whether any 
alteration in glucose disposal or insulin response to oral carnitine supplementation was 
independent of the incretin hormone response to glucose feeding. We hypothesized that lean 
active males would have higher insulin sensitivity, thus there would possibly be a greater impact 
of supplemental oral carnitine on glucose disposal and that this would be independent to the 
response of the incretin hormone glucagon-like peptide-1 (GLP-1). 
 
Methods: 
Sixteen male participants were recruited for this study which had local ethics committee 
approval. Each participant attended the laboratory on 4 occasions over a 5-6 week period. The 
first visit was for initial pre-screening which included medical history and physical activity 
questionnaires, body fat estimation (bioelectric impedance analysis, Bodystat), body mass, and 
height assessment. They then performed a three stage submaximal predicted VO2peak test on a 
cycle ergometer (Lode Excalibur, Lode, Netherlands). The three stage submaximal test started 
with 5 minutes of exercise at 50W with increases in workload determined by the heart rate 
response to exercise recorded at the end of minute 4 and minute 5 of each stage. Participants 
were recruited as lean (n=8) or overweight/obese (n=8) and their physical characteristics are 
shown in Table 1. Participants attended the laboratory one week later first thing in the morning 
after an overnight fast to perform a preliminary familiarization trial. Two days prior to this trial, 
participants were asked to record their dietary intake and to record any physical activity that 
they undertook. Participants were told not to exercise heavily during this two day period and 
were then asked to replicate their diet and activity in the two days prior to all remaining trials. 
The familiarization trial included a standard 75g, 2 hour oral glucose tolerance test (75g 
glucose, OGTT). This preliminary trial was included to ensure that all participants were 
familiarized with the OGTT protocol. 
 
The final two visits were the two main experimental trials and participants attended the 
laboratory first thing in the morning after an overnight fast (>10 hours) and on each visit 
completed a standard 75g OGTT trial. The two visits were performed following either a two 
week period of supplementation with placebo (PL, 3g/day, anhydrous glucose) or a two week 
period of supplementation with L-Carnitine L-tartrate (LC, 3g/day). Treatments were ingested in 
gelatin capsules taken as 2 capsules 3 times per day, with meals. Treatments were 
administered in a single-blind ordered fashion with placebo ingested first and with the final dose 
of supplement ingested with the evening meal on the night before the trial. An ordered design 
was used as we have previously shown that after cessation of chronic LC supplementation 
morning fasted plasma total and free carnitine can remain elevated by >10% above baseline for 
up to 3 weeks and only returns to baseline by 4 weeks after the end of an ingestion period 
(Galloway and Broad, 2004). To avoid any potential carry over effects of an elevated fasting 
plasma carnitine concentration we administered placebo first, but participants were unaware of 
this. 
 
OGTT test protocol 
After arrival at the laboratory participants had their body mass measured and then lay supine on 
a treatment couch while a cannula was inserted into an antecubital vein. Once the cannula was 
in place participants moved to a seated position and after a period of seated rest (10 min) an 
initial resting blood sample was drawn (0 min sample). Participants were then provided with a 
drink containing 75g of glucose with 15ml of a sugar free lemon flavouring made up to a total 
volume of 300ml. The drink was then consumed over a period of 1 minute and upon finishing 
the drink the OGTT timer was started. Participants remained in a seated position in a 
comfortable environment (20-22ºC) for the whole of the 2 hour OGTT period, and blood 
samples were drawn from the cannula at intervals during the test. After drawing a sample a 
small volume of sterile saline (1-2 ml) was used to flush the cannula to ensure patency. 
 
Blood sampling and analysis 
Blood samples (7.5ml) were drawn from the indwelling venous cannula at rest (0 min), at 15, 30, 
45, 60, 90 and 120 minutes during the OGTT. All blood samples were drawn into a dry syringe 
during visits 2, 3 and 4, and blood was dispensed into one 2.5ml KEDTA blood collection tube 
and one 5ml Lithium Heparin blood collection tube.  All samples were then mixed and 
immediately centrifuged at 4000 rpm for 10 minutes at 4oC.  Plasma was removed and 
transferred to microcentrifuge tubes and then frozen at –80oC until analysis. Samples were used 
for analysis of plasma glucose (glucose oxidase method, ABX diagnostics), plasma non-
esterified fatty acids (NEFA, enzymatic analysis, Alpha labs NEFA-C kit), plasma insulin (ELISA 
method, DRG human insulin kit) and total GLP-1 (Assay Technology, DRU, Novo Nordisk, 
Denmark). The total GLP-1 assay used is a two-sited immuno assay, where two antibodies 
were applied with one antibody recognizing a mid-molecular region epitope (position 15-22) and 
the other antibody specific for a C-terminus sequence (position 26-33). The assay therefore 
quantifies GLP-1 and related metabolites with amino acids from approx. position 15 to 33. The 
inter-rack assay coefficient of variation was 7.5%. Glucose and insulin data were used to 
calculate the usual insulin sensitivity indices (HOMA-IR, AUC glucose, AUC insulin) with the 
additional parameters of insulin sensitivity index, β-cell function (1st phase and 2nd phase), and 
estimated metabolic clearance rate, all calculated using the methods of Stumvoll et al (2000).  
 
Statistical analysis 
All data are expressed as mean (SEM) unless otherwise stated, and 95% confidence intervals 
are shown where appropriate. Data from the OGTT trials were analysed using a repeated 
measures analysis of variance (RMANOVA) with trial (placebo or carnitine) and time (0 min to 
120 min timepoints) as within subjects factors, and group (lean or overweight/obese) as a 
between subjects factor. Following observation of a main effect these were followed up with 
post-hoc analysis using one-way ANOVA and paired samples T-test where appropriate to 
determine at which location the differences occurred. Correlation analysis was used to 
determine whether any associations existed between BMI, estimated % body fat and predicted 
maximal aerobic capacity (corrected for lean mass) with the magnitude of the change in 
responses of the key OGTT insulin sensitivity indices between PL and LC trials. Significance 
was taken as P<0.05. 
 
Results: 
The physical characteristics of the participants are shown in Table 1. The overweight/obese 
group had a significantly higher total body mass, BMI and estimated body fat percentage, and 
also higher fat mass and lean mass than the lean group (all P<0.01). There was no difference in 
absolute VO2peak but it tended to be different when expressed per kg of lean mass (P<0.10).The 
overweight/obese group also had a significantly lower baseline calculated insulin sensitivity 
index and lower estimated metabolic clearance rate compared with the lean group on the 
placebo (PL) trial, but there was no difference in baseline HOMA-IR, AUC glucose or AUC 
insulin between groups on the PL trial (Table 2). 
 
Responses to OGTT 
There was a significant effect (P<0.01) for plasma glucose response to supplementation with a 
lower peak plasma glucose during the OGTT at 30 minutes (P<0.05) on the LC trial in the lean 
group, and a higher plasma glucose at 90 minutes (P<0.05) in the overweight.obese group on 
the LC trial, compared with the PL trial (Figure 1). Peak plasma glucose on the LC trial occurred 
at the 15 min sample time in lean and at the 45 minute sample time in overweight/obese. On the 
PL trial peak plasma glucose concentration occurred at the 30 minute sample time for both 
groups. 
 
There was no difference in the plasma insulin response to supplementation and no interactions 
were observed but there was a significant time effect (p<0.01) as expected (Figure 2). There 
was no between-subjects group effect suggesting that the insulin response to PL and LC trials 
was similar in both the lean and overweight/obese groups. Total AUC glucose and total AUC 
insulin was not significantly different between trials for either group (Table 2), however, a group 
by trial interaction was observed (P<0.05) with a decline in AUC glucose in lean from PL to LC 
trials (mean (95% CI change was -39.1 (-80.5 to 2.3) mmol.L-1 / 2 hr) and an increase in AUC 
glucose in overweight/obese from PL to LC trials (mean (95% CI) change was 47.5 (-1.2 to 
96.2) mmol.L-1 / 2 hr). There was a similar interaction with AUC insulin (P<0.05), with an 
increase in AUC insulin on LC in the overweight/obese group but no change in the lean group. 
 
There was a tendency towards a significant difference in the estimated 1st phase and 2nd phase 
beta cell function from data obtained during the OGTT trials in the lean group, with a higher 1st 
phase and higher 2nd phase beta cell function estimate on the LC trial (P<0.10, Table 2). This 
was not observed in the overweight/obese group. There was no difference in HOMA-IR, 
estimated insulin sensitivity index, or estimated metabolic clearance rate between PL and LC 
trials in either group. 
 
There was a significant time effect (P<0.01) with a decline in plasma NEFA occurring 
throughout the OGTT period in both groups (Figure 3). Total GLP-1 response during the OGTT 
was not influenced by carnitine supplementation (no trial effect, Figure 4) but there was a 
significant time effect (P<0.01), and group effect (P<0.01) with total GLP-1 significantly higher in 
the overweight/obese group than in the lean group at all time points during the OGTT. Mean 
total GLP-1 concentration throughout the protocol was 107.3(11.6) pM on PL and 112.1(15.3) 
pM on LC for the overweight/obese group, and 74.3(13.7) pM on PL and 69.7(14.3) pM on LC 
for the lean group. 
 
Associations between glucose disposal response and BMI, body fat and VO2peak 
There were significant associations between the change in AUC glucose from PL to LC trials 
with BMI, estimated % body fat and relative VO2peak (expressed relative to lean body mass). A 
positive correlation (Pearson correlation coefficient, P-value) was noted for change in AUC 
glucose with BMI (r=0.58, P=0.02) and % body fat (r=0.65, P=0.01), with a lower BMI and a 
lower % body fat associated with a greater change in AUC glucose on LC (i.e. a lower total AUC 
glucose on the LC trial compared with PL). A significant negative correlation was observed for 
change in AUC glucose to lean mass adjusted relative VO2peak (r=-0.65, P=0.01) with those 
having a higher relative VO2peak per kg lean mass also having a greater change in AUC glucose 
on LC (again meaning a lower total AUC glucose on the LC trial for more aerobically fit 
participants). 
 
Discussion: 
Oral LC supplementation (3g/day) for 2 weeks appears to have an impact upon glucose 
homeostasis and insulin release in healthy lean and overweight/obese males during a 2hr 
OGTT. Despite the lack of a baseline differences in fasting glucose, insulin and HOMA-IR, and 
the small between group differences in insulin sensitivity index and estimated metabolic 
clearance rate at baseline on the PL trial, it is clear that there are some potentially important 
group differences in blood glucose response to an OGTT following LC supplementation. 
Furthermore, the association between a greater change in AUC glucose following LC 
supplementation in those with lower body fat, lower BMI, and higher VO2peak relative to lean 
body mass suggests that fitter and leaner participants had a greater glucose disposal response 
to LC supplementation in this study. The overweight/obese participants had the opposite 
response with delayed glucose disposal. Whilst we acknowledge that administering an absolute 
amount of LC to both groups effectively means that the overweight/obese group obtained less 
LC per kg per day we wished to standardise to the OGTT protocol in which we administered 75g 
of glucose to all participants. Further studies should investigate whether matched dosing per kg 
body mass or per kg lean body mass impacts upon the outcomes noted here. 
 It is interesting that to date no-one has investigated the glucose disposal response to oral 
carnitine supplementation in healthy adults, and this current data indicates a similar pattern of 
response to that observed following carnitine infusion, at least in the lean adult males studied. 
The mechanisms behind the potentially beneficial impact of carnitine on glucose disposal have 
not been fully explored, and the promising studies on glucose disposal in patients with type 2 
diabetes in the early 1990’s have not led to large scale clinical studies. Mingrone (2004) 
published a review on carnitine in type 2 diabetes in which he concluded that carnitine is 
effective in improving insulin–mediated glucose disposal. In addition, Rahbar et al (2005) have 
observed lowering of fasting glucose following 12 weeks of carnitine supplementation in patients 
with type 2 diabetes, and Power et al (2007) have subsequently also confirmed these 
observations in a mouse model and suggest that carnitine could be used as an adjunctive 
therapy in diabetes. Furthermore, Poorabbas et al (2007) have observed that plasma carnitine 
concentration is significantly lower in patients with complications associated with their type 2 
diabetes (retinopathy, neuropathy and hyperlipidaemia). However, some confusion exists in the 
literature due to other studies which have not observed these beneficial actions of carnitine in 
type 2 diabetes patients (Gonzalez-Ortiz et al 2008). Therefore, the current data adds to the 
literature by demonstrating that oral carnitine supplementation in healthy lean adults has similar 
effects to those observed following infusion of carnitine. The data supports the notion that this 
effect is likely independent of changes in insulin or GLP-1 response to glucose feeding and thus 
points towards a direct effect of carnitine on skeletal muscle glucose uptake. Interestingly, this 
pattern of response is not observed in the overweight/obese adults studied and the response in 
that group suggests that further work should be conducted to examine differences in substrate 
handling/disposal between lean and overweight/obese adults with nutritional supplement 
interventions. 
 
Responses to OGTT 
The blunting of peak glucose concentration to a glucose challenge following LC 
supplementation despite similar insulin release for lean adult males in the present study 
indicates that LC could either have a direct ‘insulin like’ or sensitising effect on tissues, or could 
play a metabolic role in buffering acyl groups in β–cell mitochondrial metabolism which would 
act to maintain glucose oxidation and thus potentially enhance insulin release for a given 
glucose concentration (Newsholme et al 2005). Indeed, the potential for LC to reduce peak 
plasma glucose through a direct ‘insulin like’ action on tissues is supported by previous 
observations of ‘insulin like’ actions on rat cardiac muscle (Rodgers et al 2001) and the 
observed increased skeletal muscle glycogen storage following carnitine infusion in humans 
(Stephens et al 2006a). This ‘insulin-like’ action of LC could explain the earlier and lower peak 
glucose concentration observed in the lean group during the OGTT in the present study. 
However, this proposed action is not consistent with the observed higher mean glucose 
concentration at the 90 min sample time on the LC trial in the overweight/obese group. Indeed, 
the overweight/obese group demonstrated a higher blood glucose concentration at 90 min on 
the LC trial due to a delayed peak glucose response to feeding. 
 
Therefore, the pattern of response in plasma glucose suggests that supplemental oral carnitine 
can influence glucose disposal in response to carbohydrate feeding (at least in lean active 
subjects) and could also partly explain the elevated muscle glycogen data observed following 
carnitine infusion and hyperinsulinaemia by Stephens et al (Stephens et al 2006a). Furthermore, 
these enhanced glucose disposal and glycogen storage effects could explain the increased 
reliance on carbohydrate oxidation in endurance trained athletes following a 2 week period of 
carnitine supplementation combined with a high-carbohydrate diet (Abramowicz and Galloway 
2005). Further work with larger sample sizes is required to examine lean vs. overweight/obese 
group differences in response to LC supplementation and to determine whether these could be 
related to differences in habitual diet composition. Diet was controlled for each trial but not 
standardised between groups in the present study and the food records were not detailed 
enough to warrant full dietary analysis. 
 
The potential effects of LC supplementation on insulin secretion through maintenance of 
glucose or fatty acid oxidation in the β-cell by buffering of acyl-groups, or through generation of 
glutamate for maintenance of ATP/ADP ratio in the β-cell are also attractive hypotheses, as 
these mechanisms of action have been demonstrated for other amino acids which have been 
shown to enhance insulin secretion (Newsholme et al 2005). We do not have any direct 
evidence from the present study to support an effect on pancreatic glucose or fatty acid 
metabolism but carnitine is known to play a key role in buffering acyl group accumulation in 
skeletal muscle (Roepstorff et al 2005) and could act in a similar manner in pancreatic cells to 
assist in maintenance of ATP/ADP ratio and thus provide optimal conditions for promoting 
insulin release. Furthermore, we have previously shown that LC supplementation over the same 
time period used in the present study resulted in an increased resting plasma glutamate 
concentration (Broad et al 2008) which may support changes to β-cell function. However, 
without a significant increase in insulin secretion response during the OGTT following LC 
supplementation it seems likely that these acyl group buffering mechanisms or enhanced 
glutamate supply may not explain the observations we have made. The tendency towards an 
increase in estimated first and second phase β–cell function suggests a greater early release of 
insulin in relation to plasma glucose concentration in response to glucose feeding after LC 
supplementation, however, this could reflect either reduced rate of glucose entry into the 
circulation or increased rate of glucose removal from the circulation. These two actions would 
occur through the mechanisms already discussed (direct insulin-like actions) or alternatively 
could occur through a change in gastric emptying rate or alteration in incretin hormone (GLP-1 
or GIP) response to glucose feeding.  
 
Gastric emptying rate has not previously been investigated in human LC supplementation 
studies but data in rats do not support an acute carnitine mediated reduction in gastric emptying 
rate (Matsuda et al 1998). However, the response of both glucose and insulin in the 
overweight/obese group in the present study appear to reflect a change in glucose delivery to 
the circulation which would likely be related to an altered gastric emptying or intestinal transport 
of glucose in the LC trial. Given the effect that prior protein meal ingestion can have on gastric 
emptying and glucose response to carbohydrate feeding (Ma et al 2009) it would be interesting 
to speculate that chronic LC supplementation or acute ingestion of the last dose the evening 
before the OGTT may be acting to influence glycaemic response to feeding through delayed 
gastric emptying in overweight/obese participants. From the present data, this could potentially 
explain the delay in peak glucose concentration on the LC trial in the overweight/obese group 
but is not consistent with the response observed in the lean group. Therefore, further work is 
required to investigate any effects of acute/chronic carnitine feeding on gastric emptying of 
glucose solutions in overweight/obese adults. 
 
Alternatively, if LC had altered the GLP-1 response to feeding this could also explain our 
observations. GLP-1 is one of the main incretin hormones responsible for altering the glucose 
and insulin response to feeding through an action of ingested nutrients on intestinal L-cell GLP-
1 release (Deacon, 2005; Holst, 2007). GLP-1 can act on the pancreas to stimulate insulin 
secretion, but can also reduce glucagon secretion and delay gastric emptying, thus having a 
multifaceted action on glucose homeostasis (Baggio and Drucker, 2007). However, the present 
data clearly demonstrate that LC supplementation does not impact upon total GLP-1 response 
to glucose feeding. The observed higher total GLP-1 concentration throughout the protocol in 
overweight/obese and the interaction between trial and group may add further support to the 
notion that there are differential effects of LC supplementation on responses to glucose feeding 
in lean vs. overweight/obese groups. 
 
However, it must be acknowledged that our total GLP-1 data should be interpreted with some 
caution as the resting plasma total GLP-1 concentration is high on both trials in both groups of 
participants. It may be that storage of our plasma samples has led to high fasting GLP-1, or that 
the baseline samples which were obtained 10 minutes after venous cannulation reflect a stress 
induced response of GLP-1 to the cannulation procedure. Indeed, stress induced sympathetic 
activation has been shown to result in enhanced early release of other gut peptides (Zhang et al 
1993) and may be responsible for the high fasted GLP-1 values observed in the present study. 
This is despite a familiarisation trial involving the cannulation procedure being conducted. We 
are unaware of any studies specifically examining stress hormone induced elevation in total 
GLP-1 in humans, and studies in animal models are at best inconclusive (Kinzig et al 2003); 
(Azlina et al 2005). Storage studies do not suggest an influence on GLP-1 concentration but do 
indicate that standardisation of evening meal on the night before trials should be performed 
(Chandarana et al 2009). Given that participants in the present study replicated their diet and 
activity for 2 days prior to each trial this should not have been an issue in the present work, but 
we cannot rule out a potential acute or chronic effect of ingestion of the carnitine supplement on 
the evening or days before the LC trial. 
 
Conclusions 
We can therefore conclude that supplementation with LC appears to influence glucose 
homeostasis in response to OGTT. This size and nature of this response is different between 
lean and overweight/obese adult males and appears to be related to body fat, BMI and VO2max 
expressed relative to lean body mass. The pattern of response in glucose with LC 
supplementation in lean participants (earlier timing of peak glucose and lower 30 min glucose 
concentration) seems to support a mechanism of enhanced glucose disposal through a direct 
insulin-like action on skeletal muscle. The pattern of change in overweight/obese with LC 
(delayed timing of peak glucose and higher 90 min glucose concentration) appears to support 
delayed gastric emptying but these observations need further evaluation. This differential 
response to an OGTT in lean and overweight/obese participants following oral LC 
supplementation could explain some of the conflicting reports on metabolic responses to 
carnitine supplementation evident in the literature. 
Table 1: Physical characteristics of participants in lean and overweight/obese groups. Values 
are mean±SD (95% CI). 
Variable Lean Overweight/obese 
n 8 8 
Age (yr) 24.0±7.4 (18.9-29.1) 29.0±9.9 (22.2-35.8) 
Height (cm) 180.0±5.8 (176.0-184.0) 178.7±6.7 (174.1-183.3) 
Body mass (kg) 76.1±5.6 (72.2-80.0)* 103.3±13.0 (94.3-112.3)* 
BMI (kg/m2) 23.5±1.0 (22.8-24.2)* 32.5±4.9 (29.1-35.9)* 
Estimated body fat (%) 12.3±2.9 (9.3-14.3)* 25.9±6.3 (21.5-30.3)* 
Fat mass (kg) 9.3±2.2 (7.8-10.8)* 27.3±9.4 (20.8-33.8)* 
Lean mass (kg) 66.8±5.7 (62.9-70.7)* 76.0±6.2 (71.7-80.3)* 
Fasting glucose (mmol/L) 5.6±(5.2-6.0) 5.2±(4.7-5.7) 
Fasting insulin (µIU/ml) 6.9±(5.6-8.2) 15.4±(5.8-23.8) 
VO2peak (L
.min-1) 4.12±0.65 (3.67-4.57) 4.01±0.90 (3.38-4.64) 
VO2peak (mL
.kg lean-1.min-1) 61.3±6.2 (57.0-65.6)† 52.8±10.9 (45.2-60.4)† 
* significantly different between lean and overweight/obese groups (P<0.05). 
† indicates tendency towards statistical significance between groups (P<0.10). 
 
  
Table 2: Oral glucose tolerance test insulin sensitivity indices of participants in lean and 
overweight/obese groups on placebo (PL) and L-Carnitine (LC) supplemented trials. Values are 
mean (95% CI). No statistically significant differences were noted in variables between PL and 
LC trials within each group. 
Variable Trial Lean Overweight/obese 
HOMA-IR (arbitrary units) 
 
PL 
LC 
1.7 (1.4-2.0) 
2.1 (1.6-2.6) 
3.5 (1.3-5.7) 
3.2 (1.7-4.7) 
AUC glucose (mM/2hr) 
 
PL 
LC 
153 (121-186) 
114 (97-131)‡ 
265 (98-432) 
312 (99-526)‡ 
AUC insulin (pM/2hr) 
 
PL 
LC 
3739 (2480-4998) 
3414 (2029-4799)‡ 
6117 (3087-9147) 
7536 (4256-10816)‡ 
1st phase β–cell function (pM) 
 
PL 
LC 
223 (18-428) 
409 (305-513)† 
340 (193-487) 
428 (315-541) 
2nd phase β–cell function (pM) 
 
PL 
LC 
93 (55-131) 
129 (109-149)† 
117 (88-146) 
135 (112-158) 
Insulin sensitivity index (µmol.kg-1.min-1.pM-1) PL 
LC 
0.13 (0.13-0.13)* 
0.13 (0.13-0.13)* 
0.09 (0.08-0.10)* 
0.09 (0.08-0.10)* 
Metabolic clearance rate (mg.kg-1.min-1) PL 
LC 
10.9 (10.7-11.1)* 
10.9 (10.7-11.1)* 
7.9 (6.7-9.1)* 
7.8 (6.5-9.1)* 
* significantly different between lean and overweight/obese groups (P<0.01). 
‡ significant interaction between trial and group (P<0.05). 
† indicates tendency towards statistical significance between PL and LC trials within group 
(P<0.10). 
 
  
Figure legends: 
 
FIGURE 1. Plasma glucose response to OGTT on placebo (PL) and L-carnitine (LC) trials in 
lean (Lean, n=8) and overweight/obese (Obese, n=8) groups. Values are mean (SEM). * 
indicates significant difference (P<0.05) from PL. 
 
FIGURE 2. Plasma insulin response to OGTT on placebo (PL) and L-carnitine (LC) trials in lean 
(Lean, n=8) and overweight/obese (Obese, n=8) groups. Values are mean (SEM). No 
differences were observed between trials. 
 
FIGURE 3. Plasma NEFA response to OGTT on placebo (PL) and L-carnitine (LC) trials in lean 
(Lean, n=8) and overweight/obese (Obese, n=8) groups. Values are mean (SEM). No 
differences were observed between trials. 
 
FIGURE 4. Plasma total GLP-1 response to OGTT on placebo (PL) and L-carnitine (LC) trials in 
lean (Lean, n=8) and overweight/obese (Obese, n=8) groups. Values are mean (SEM). No 
differences were observed between trials. 
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